Effects of xenogeneic transplantation of umbilical cord-derived mesenchymal stem cells combined with irbesartan on renal podocyte damage in diabetic rats
Open Access
- 30 July 2024
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-15
Abstract
Background: The leading cause of end-stage renal disease (ESRD) is diabetic nephropathy (DN). Podocyte damage is an early event in the development of DN. Currently, there is no effective treatment strategy that can slow the progression of DN or reverse its onset. The role of mesenchymal stem cells (MSCs) transplantation in diabetes and its complications has been extensively studied, and diabetic nephropathy has been a major focus. Irbesartan exerts reno-protective effects independent of lowering blood pressure, can reduce the incidence of proteinuria in rats, and is widely used clinically. However, it remains undetermined whether the combined utilization of the angiotensin II receptor antagonist irbesartan and MSCs could enhance efficacy in addressing DN. Methods: A commonly used method for modeling type 2 diabetic nephropathy (T2DN) was established using a high-fat diet and a single low-dose injection of STZ (35 mg/kg). The animals were divided into the following 5 groups: (1) the control group (CON), (2) the diabetic nephropathy group (DN), (3) the mesenchymal stem cells treatment group (MSCs), (4) the irbesartan treatment group (Irb), and (5) the combined administration group (MSC + Irb). MSCs (2 × 106 cells/rat) were injected every 10 days through the tail vein for a total of three injections; irbesartan (30 mg/kg/d) was administered by gavage. Additionally, the safety and homing of mesenchymal stem cells were verified using positron emission tomography (PET) imaging. Results: The combination treatment significantly reduced the UACR, kidney index, IGPTT, HOMA-IR, BUN, serum creatine, and related inflammatory factor levels and significantly improved renal function parameters and the expression of proteins related to glomerular podocyte injury in rats. Moreover, MSCs can homing target to damaged kidneys. Conclusions: Compared to the administration of MSCs or irbesartan alone, the combination of MSCs and irbesartan exerted better protective effects on glomerular podocyte injury, providing new ideas for the clinical application of mesenchymal stem cells.Keywords
All Related Versions
Funding Information
- Natural Science Research of Jiangsu Higher Education Institutions of China (No. 18KJA350002)
- Natural Science Foundation of Jiangsu Province (No. BK20181470)
- Natural Science Foundation of China (No. 82173883)
- Science and Technology Foundation of Xuzhou (No. KC22469)
This publication has 65 references indexed in Scilit:
- The therapeutic effect of mesenchymal stem cells in diabetic kidney diseaseJournal of Molecular Medicine, 2024
- Repurposing iron chelators for accurate positron emission tomography imaging tracking of radiometal‐labeled cell transplantsMedcomm, 2024
- Repeated administration of adipose-derived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease ratBiomedical Journal, 2023
- Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney DiseaseCurrent Medical Science, 2020
- Differences in serum proteins in traditional Chinese medicine constitutional population: Analysis and verificationJournal of Leukocyte Biology, 2020
- Diabetic Nephropathy: An Overview2019
- Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic NephropathyThe American Journal of the Medical Sciences, 2018
- Mesenchymal Stem Cell-Based Therapies against Podocyte Damage in Diabetic NephropathyTissue Engineering and Regenerative Medicine, 2017
- Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic ratsEndocrine, 2013
- The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathyActa Histochemica, 2011